Monopar Therapeutics (MNPR) Set to Post Quarterly Earnings on Thursday

Key Points

• Monopar Therapeutics is expected to report Q3 2026 results before the market opens Nov. 12, with analysts forecasting a loss of $0.86 per share. The company’s previous quarter loss of $0.62 per share was narrower than estimates.
• Analysts have a “Moderate Buy” consensus rating and an average price target of $122; ratings include six Buys, one Strong Buy, two Holds and one Sell.
• Company insiders sold 51,920 shares worth about $4.53 million over the past 90 days. The stock opened at $72.81 and has traded between $50.07 and $124.82 over the past year.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Monopar Therapeutics to announce earnings of ($0.86) per share for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 12:30 PM ET.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02. On average, analysts expect Monopar Therapeutics to post ($2.98) EPS for the current fiscal year and ($4.29) EPS for the next fiscal year.

Monopar Therapeutics Stock Up 4.2%

Monopar Therapeutics stock opened at $72.81 on Thursday. The company has a 50 day moving average of $88.66 and a 200-day moving average of $77.40. Monopar Therapeutics has a twelve month low of $50.07 and a twelve month high of $124.82. The stock has a market capitalization of $488.56 million, a PE ratio of -33.55 and a beta of 1.62.

Insider Buying and Selling

In related news, Director Kim Tsuchimoto sold 2,891 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $71.26, for a total transaction of $206,012.66. Following the completion of the transaction, the director directly owned 1,199 shares of the company's stock, valued at approximately $85,440.74. This represents a 70.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the firm's stock in a transaction that occurred on Thursday, September 24th. The shares were sold at an average price of $88.00, for a total value of $2,556,928.00. Following the completion of the transaction, the chief executive officer owned 99,267 shares of the company's stock, valued at approximately $8,735,496. This represents a 22.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 51,920 shares of company stock worth $4,527,913. Insiders own 9.70% of the company's stock.

Analyst Upgrades and Downgrades

MNPR has been the topic of several research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Thursday, October 15th. Cantor Fitzgerald cut shares of Monopar Therapeutics from an "overweight" rating to a "neutral" rating and raised their price target for the stock from $109.00 to $119.00 in a research note on Thursday, August 13th. Morgan Stanley reaffirmed an "overweight" rating and set a $130.00 price target on shares of Monopar Therapeutics in a research note on Monday, August 17th. HC Wainwright boosted their price objective on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a "buy" rating in a research report on Wednesday, July 22nd. Finally, UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a report on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Monopar Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $122.00.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company's research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar's pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.